Please provide your email address to receive an email when new articles are posted on . The FDA has approved subcutaneous administration of Takeda Pharmaceuticals’ Entyvio for maintenance therapy in ...
Credit: Takeda. The approval was based on data from the phase 3 VISIBLE 2 trial. Results showed 48% of patients treated with vedolizumab SC were in clinical remission at week 52 compared with 34% of ...
Entyvio (vedolizumab) is a prescription drug that’s used to treat ulcerative colitis and Crohn’s disease. It’s not known whether Entyvio is safe to use while pregnant or breastfeeding. If you can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results